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CONDENSATION 
 
 
Higher anticipated pain is associated with increased discomfort during intrauterine device 
placement. 
 
SHORT VERSION OF TITLE 
 
Discomfort with Intrauterine Device Placement.  
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ABSTRACT 
 
Background:  Intrauterine Devices (IUDs) have been gaining popularity for the past 2 
decades. Current data reports that more than 10% of women using contraception are using an 
IUD. With less than 1% failure rates, IUDs are one of the most effective forms of long acting 
reversible contraception, yet evidence shows that fear of pain during IUD placement deters 
women from choosing an IUD as their contraceptive method.  
Objective(s): The objective of this analysis was to estimate the association between 
anticipated pain with IUD placement and experienced pain. We also assessed other factors 
associated with increased discomfort during IUD placement. We hypothesized that patients 
with higher levels of anticipated pain would report a higher level of discomfort during 
placement.  
Study Design: We performed a secondary analysis of the Contraceptive CHOICE Project 
(CHOICE). 9,256 patients were enrolled in CHOICE from the St. Louis region between 2007 
and 2011, of which 1,149 subjects presenting for their first placement of either the original 
52mg LNG IUS or the copper IUD were analyzed in this study. Patients were asked to report 
their anticipated pain prior to IUD placement and experienced pain during placement on a 10-
point visual analog scale. We assessed the association of anticipated pain as well as patient 
demographic and reproductive characteristics and IUD type with experienced pain with IUD 
placement.  
Results:   The mean age of CHOICE participants in this subanalysis was 26 years. Of these 
1,149 study subjects, 44% were black and 53% were of low socioeconomic status. The median 
expected pain score was 5 for both the LNG-IUS and the copper IUD while the median 
experienced pain score was 5 for the LNG-IUS and 4 for the copper IUD. After controlling for 
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parity, history of dysmenorrhea, and type of IUD, patient anticipated pain was associated with 
increased experienced pain (adjusted relative risk for one unit increase in anticipated pain = 
1.19, 95% confidence interval 1.14, 1.25). Nulliparity, history of dysmenorrhea, and the 
hormonal IUD (compared to copper) were also associated with increased pain with IUD 
placement.  
Conclusion(s): High levels of anticipated pain correlated with high levels of experienced pain 
during IUD placement. Nulliparity and a history of dysmenorrhea were also associated with 
greater discomfort during placement. This information may help guide and treat patients as 
they consider IUD placement. Future research should focus on interventions to reduce pre-
procedural anxiety and anticipated pain to potentially decrease discomfort with IUD placement. 
Key Words: Intrauterine device insertion, placement, pain, discomfort, anticipated pain, 
nulliparity, dysmenorrhea 
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INTRODUCTION 
Intrauterine devices (IUDs), including the copper (TCu830A) and the hormonal IUD 
(levonorgestrel intrauterine system or LNG-IUS), are two of the most effective forms of 
reversible contraception available; failure rates are less than 1% for both perfect and typical 
use.1 Multiple studies have demonstrated high levels of acceptability of IUDs and continuation 
rates at 2-3 years are in the range of 67-77%.2,3 In fact, continuation rates for IUDs are higher 
than those for shorter-acting reversible contraceptive methods, such as the pill, ring, 
contraceptive patch, or depo-medroxyprogesterone acetate (DMPA).3 The rate of use of IUDs 
in the US has steadily increased in the last 2 decades. The most recently published data 
demonstrates 10.3% of contracepting women aged 15-44 are using an IUD.4 Though highly 
effective and acceptable, qualitative and anecdotal evidence has suggested that perceived 
pain with placement may be a barrier to the use of intrauterine contraception.5  
Few small studies have been published evaluating predictors of increased pain with IUD 
placement and results have been inconsistent. Factors that have been associated with more 
significant pain at the time of IUD placement include nulliparity6-9 or no prior vaginal delivery,10 
age greater than 30 years,8 a longer interval since last pregnancy or menses,7,8 a history of 
dysmenorrhea,6,11 absence of current breastfeeding,7,8 and higher educational achievement.7 
Additionally, higher anxiety preceding the procedure, or higher expected pain with placement 
have been associated with greater pain at the time of placement.10,12-14 Explaining the pros and 
cons of IUDs, guidance on what to expect during and after the procedure, and suggestion of 
coping mechanisms like distraction techniques prior to placement have been proposed as 
methods to decrease pain with placement.15  
 The purpose of this secondary analysis was to describe the pain or discomfort 
  
 
6 
experienced with IUD placement, and to assess whether anticipated or expected pain is 
associated with discomfort experienced with placement. We also sought to evaluate the 
association of demographic or psychological factors with increased pain with placement. Our 
specific hypothesis was that subjects with higher levels of anticipated pain with placement 
would score higher on our scale of reported discomfort with placement. 
 
MATERIALS & METHODS 
We performed a secondary analysis of the women undergoing IUD placement in the 
Contraceptive CHOICE Project (CHOICE). CHOICE was a prospective cohort study that 
educated all participants about contraceptive methods, including the most effective methods 
(IUDs and the contraceptive implant). CHOICE reduced access obstacles to contraception and 
provided all methods at no cost. The goal of the study was to reduce the unintended 
pregnancy rate in the St. Louis region.3 The methods of CHOICE have been previously 
described in this journal;16 we will briefly outline the substudy methods here. 
CHOICE project participants were between the ages of 14 and 45 years, and were 
enrolled between August 2007 to September 2011. Inclusion criteria for CHOICE were as 
follows: 1) sexually active or planning to become sexually active with a male partner within the 
next six months; 2) willing to begin using or switch to a new reversible method of 
contraception; and 3) English or Spanish speaking. If individuals wanted to conceive in the 
next 12 months or had undergone a hysterectomy or sterilization procedure, they were not 
eligible to participate in CHOICE. Participants were eligible for this secondary analysis if they 
chose an IUD (the original 52mg LNG IUS (Bayer, Whippany, NJ) or copper) for their 
contraceptive method and had their expected and experienced pain assessed at the 
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placement visit (questions regarding pain with placement were added November, 2010). Our 
analysis included each participant once. If a woman had multiple IUD placements during her 
participation in CHOICE, only the first CHOICE placement was included in the dataset. We did 
not exclude women who had previously had an IUD prior to CHOICE enrollment. The 
Washington University in St. Louis institutional review board approved the study protocol and 
all participants provided written informed consent.  
All subjects were asked to complete a baseline questionnaire. We collected 
comprehensive demographic and reproductive data as well as information regarding sexual 
activity, medical, and surgical history. At the baseline interview, women were asked “During 
the past 12 months, on average, how often did you have pain or cramping during your period?” 
Women were categorized as having a history of dysmenorrhea if they answered “often” or 
“always;” participants responding “sometimes” or “never” were considered our referent group. 
Patients were considered to have a history of depression and/or anxiety if they provided an 
affirmative response to the question, “have you ever had depression/anxiety?” 
In CHOICE, many different providers (e.g. nurse practitioners, residents, fellows, and 
attending physicians) inserted IUDs; however, most (>80%) were done by nurse practitioners. 
In the few minutes prior to placement of their chosen IUD, women were asked to describe the 
pain they anticipated experiencing with the IUD placement on a 10-point visual analog scale 
(VAS). In the few minutes after placement, participants were asked to rate their actual 
experienced pain on the same scale. This information was collected by the same provider who 
placed the IUD and was recorded along with the type of IUD placed.  
The primary outcome of this study was the patients’ score of the level of actual pain 
experienced during the IUD placement. Pain experienced during the IUD placement was 
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analyzed two ways: 1) as a continuous variable; and 2) dichotomized into experienced pain 
less than 7 (low pain score) vs greater than or equal to 7 (high pain score). We chose a value 
of 7 on the pain scale as a clinically meaningful value that would be understandable to 
providers interpreting these data for clinical use.  
 We considered a participant to be of “low SES” if they answered "yes" to either of the 
following questions: “do you currently receive food stamps, WIC, Welfare, and/or 
unemployment?” or “during the past 12 months, have you had trouble paying for 
transportation, housing, health, medical care or medications, and/or food?” We did not use 
household income in our definition, as many adolescents were cohabitating with parents or 
guardians, and could not provide accurate household income data.  
Patient characteristics were summarized using mean and standard deviation, median 
and range, or frequency and percentage depending on data type. Student t test or chi-square 
test were used to compare the patient characteristics between two IUD types. Our primary 
exposure variable in this analysis was anticipated pain with IUD placement. When experienced 
pain was treated as a continuous variable, linear regression models were used to estimate the 
change in experienced pain with placement. When experienced pain was treated as a 
dichotomized variable, Poisson regression models with robust variance were used to estimate 
the relative risk for high pain. Demographic and reproductive characteristics and IUD type were 
evaluated for potential confounding effect in the association between anticipated and 
experienced pain. Confounding was defined as a greater than 10% relative change in the 
association between anticipated and experienced pain with or without the potential 
confounding covariate in the model. Confounders were included in the final multivariable 
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model. All the statistical analyses were performed using Stata software, version 11 
(StataCorp). The significance level (alpha) was set at 0.05. 
 
RESULTS 
Of the 9256 CHOICE participants, there were 4,302 IUD placements. Of these 
placements, we collected information regarding anticipated and experienced pain in 1,208 
participants. Once we excluded multiple IUD placements, 1,149 IUD first placements remained 
in our dataset. 
Table 1 provides the demographic, reproductive, and other patient characteristics of our 
study sample. The mean age was 26.1 years. Women choosing a LNG-IUS were significantly 
younger than women choosing the copper IUD (mean age 25.8 vs. 27.3 respectively; p<0.01). 
Black women were significantly more likely to choose LNG-IUS (46.4% vs. 34.8%; p<0.01) 
while white women were significantly more likely to choose the copper IUD (58.5% vs. 47.2%; 
p<0.01). There were no other patient demographics or characteristics associated with the type 
of IUD chosen. Notably, there was no significant difference in choice of IUD type in regards to 
a woman’s history of dysmenorrhea or level of pain she anticipated with the procedure.  
The median expected pain score on the VAS was 5 (range: 0-10, mean=5.2, standard 
deviation (s.d.)=2.5) and expected pain was similar for women undergoing placement of both 
IUD types (LNG-IUS: median=5, range: 0-10, mean=5.1, s.d.=2.5; copper IUD: median=5, 
range: 0-10, mean=5.2, s.d.=2.4). The median experienced pain with IUD placement on the 
VAS was also 5 (range: 0-10, mean=5.0, s.d.=2.5). For women who had the LNG-IUS placed, 
median experienced pain score was 5 (range: 0-10, mean=5.1, s.d.=2.5); for the copper IUD, 
median experienced pain score was 4 (range: 0-10, mean=4.71, s.d.=2.4). 
  
 
10 
Experienced pain with IUD placement by the participant demographics and 
characteristics is shown in Table 2. In our unadjusted analysis, the following factors were 
associated with increased risk of high pain score with IUD placement: young age (<20 years), 
non-black race, single and/or never married; normal body mass index (BMI); having private or 
no insurance; nulliparity; having no history of unintended pregnancy or termination of 
pregnancy; history of dysmenorrhea; and higher anticipated pain score.  
Table 3 shows results of the multivariable model. Four characteristics were found to be 
significantly associated with the risk of a high pain score in our adjusted model: level of 
expected pain, parity, history of dysmenorrhea, and the type of IUD chosen. For each 
additional “point” of pain expected on the VAS, a woman was 19% more likely to experience 
high pain (score > 7) during placement (relative risk (RR)=1.19). Increasing parity was 
associated with experiencing less pain with placement. Women who had the LNG-IUS placed 
were more likely to experience high pain as compared to women who had the copper IUD 
placed (RR=1.31, 95% CI: 1.05-1.63). Women who reported a history of dysmenorrhea were 
also more likely to experience high pain (RR=1.53, 95% CI: 1.28-1.83). The results from the 
linear regression lead to the same conclusions (data not shown). 
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COMMENT 
 
In our analysis of over 1,000 IUD placements, we found that women with higher levels 
of anticipated pain were more likely to experience increased discomfort during placement, 
supporting our hypothesis. We also noted that nulliparity, history of dysmenorrhea, and 
placement of the LNG-IUS, compared to the copper IUD, were associated with higher pain 
scores. 
Our finding that increased anticipated pain was associated with increased experienced 
pain with IUD placement is consistent with previous publications.10,12-14 Though an explanation 
for this finding has not yet been noted in the literature, studies involving other procedures such 
as cystoscopy and urodynamic procedures provide greater detail.17-19 Shaw conducted a 
qualitative study which focused on patients’ feelings about urodynamics procedures to isolate 
reasons contributing to patients’ emotional and physical discomfort throughout the 
procedures.19 By recording unstructured interviews, researchers recognized anxiety and fear of 
embarrassment as key components correlated with increased discomfort during procedures. 
Several patients reported experiencing less anxiety after having friendly conversations with 
nurses and physicians, unrelated to the procedure. Simple conversations with healthcare 
professions can put patients at ease with the procedure at hand, reducing anxiety levels and in 
turn, decreasing discomfort at the procedure. On the other hand, conversing extensively about 
the procedure has not been shown to reduce experienced discomfort.17  
Our finding that nulliparity is associated with increased risk of high pain during IUD 
placement, is also consistent with findings reported elsewhere.6-10,14 In a case-control study of 
factors associated with severe pain with IUD placement, women with parity less than 3 were 
more likely to experience severe pain compared to women with higher parity.7 Allen et al. 
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reported that women with no prior vaginal delivery were more likely to have increased pain with 
IUD placement, regardless of whether they were nulliparous or had only delivered via 
cesarean; this effect was still noted in women who had some degree of cervical dilation prior to 
cesarean.10  
Other studies have found an increased risk for high pain score in women with a history 
of dysmenorrhea.6,11 Dysmenorrhea may be associated with changes in uterine blood flow and 
hypercontractility.11,20,21 Women with severe dysmenorrhea have altered CNS responses to 
pain, differences in steroid hormone levels, and differ from women without dysmenorrhea in 
several immunologic factors.22-24 These same factors may predispose to pain with IUD 
placement. 
We noted that women who had LNG-IUS placed were significantly more likely to report 
a high pain score than women who chose the copper IUD. The diameter of the original 52mg 
LNG IUS inserter tube (which was the only hormonal LNG-IUS used in CHOICE) was 4.8 mm 
at the time CHOICE IUD placements took place25 while the copper IUD insertion tube was 4.39 
mm +/- 0.1 mm.26 In 2012, after CHOICE recruitment was complete, the original 52mg LNG 
IUD inserter became 4.4 mm. Studies of IUD type and discomfort with placement have been 
mixed. One 2015 study using the 4.8 mm inserter agreed with our findings.14 Two other studies 
found no difference in pain with LNG-IUS versus copper IUD placement.6,11 Of these two 
studies, Kaislasuo et al. compared the copper IUD inserter tube to both the 4.8 mm and 4.4 
mm LNG-IUD inserter,11 and Weibe reported on placements that took place in 2013 (after the 
new inserter had been introduced) but did not specify on the size of the tube used.6 
One prior study found that women older than 30 years were more likely to experience 
high pain with IUD placement.8 However, we found no relationship between age and 
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experienced pain, even when we analyzed age as a continuous or categorical variable. 
Similarly, we found no association between level of education and experienced pain, which 
differs from one other report.7  
Several trials have attempted to identify methods for reducing pain with the IUD 
placement procedure. A Cochrane review published in 2015 and several subsequent trials 
have demonstrated some modest benefit in decreasing pain with lidocaine 4% topical gel in 
nulliparous women, lidocaine 10% spray in parous women, lidocaine 1% paracervical block, 
and a combined lidocaine-prilocaine cream.27-32 Tramadol and naproxen, but not ibuprofen, 
have been shown to have a modest effect on reducing pain with placement in parous women 
or within a short time frame after placement for nulliparous women;29,33 neither diclofenac nor 
ketorolac have shown clinical significance in pain reduction.34,35 
Various studies have reported on misoprostol use prior to IUD placement. A meta-
analysis of most published data on misoprostol indicates that misoprostol is associated with no 
improvement in pain, and occasionally in increased pain and unpleasant side effects.29 Only 
one study has shown misoprostol to decrease pain with IUD placement.36 Studies of nitric 
oxide donors, in the forms of nitroprusside gel, nitroglycerin ointment, and inhaled N2O/O2 
have all shown no improvement in pain with placement.37-39 Use of a vulsellum instead of a 
single-toothed tenaculum also does not appear to reduce pain experienced.14 
 One strength of the analysis presented here is the large sample size of IUD placements 
with prospective data collection of anticipated and experienced pain. As a prospective cohort 
study, CHOICE was able to reduce the possibility of recall bias as data regarding anticipated 
and actual pain were collected in real time. One limitation of the data presented here is the 
limited details regarding any interventions used by clinicians and CHOICE participants at the 
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time of IUD placement. Non-steroidal anti-inflammatory drugs (NSAIDS) were routinely offered 
to participants prior to IUD placement, and almost all women accepted this premedication. 
Lidocaine was rarely used for IUD placement in CHOICE, and was reserved for more difficult 
insertions. Unfortunately, information regarding NSAID and lidocaine use was not routinely 
collected. We do not believe this has an appreciable impact on our results, given routine use of 
NSAID and very rare use of lidocaine. Given the recruitment years of the CHOICE study 
(2007-11), we are not able to address pain with placement for other IUDs, such as LNG-IUS 
devices that are smaller or have a different dose of levonorgestrel or a different inserter. All 
participants were from a single, large midwestern city in the U.S., and this population may not 
be generalizable to the US population.  
 In summary, we found that higher anticipated pain was associated with discomfort 
experienced during IUD placement. In addition, nulliparity, a history of dysmenorrhea, and 
placement of the hormonal IUD (with a 4.8mm inserter) were associated with a higher 
placement pain scores. Our data may allow providers the opportunity to personalize their 
approach to IUD placement with appropriate, risk-factor based counseling prior to placement of 
an IUD. For example, a nulliparous patient with a history of dysmenorrhea and high anticipated 
pain or anxiety may benefit from additional patient-tailored counseling and offering evidence-
based options for pain control. Researchers should focus future studies on interventions to 
reduce pre-procedural anxiety and anticipated pain, with a goal of decreasing discomfort with 
IUD placement. 
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Table 1: Patient demographic and reproductive characteristics by type of intrauterine 
device. 
        
  All (n=1149) 
LNG-IUS 
(n=862) 
Copper IUD 
(n=287)   
  Mean SD Mean SD Mean SD p-value 
Age               
  26.1 5.9 25.8 5.6 27.3 6.4 <0.01 
  N % N % N %   
Age group             0.66 
<20 years old 116 10.1 89 10.3 27 9.4   
>=20 years old 1033 89.9 773 89.7 260 90.6   
Race             <0.01 
Black 500 43.5 400 46.4 100 34.8   
White 575 50.0 407 47.2 168 58.5   
Others 74 6.4 55 6.4 19 6.6   
Ethnicity             0.54 
Hispanic 45 3.9 32 3.7 13 4.5   
Non-Hispanic 1104 96.1 830 96.3 274 95.5   
Education             0.25 
<=HS 242 21.1 189 21.9 53 18.5   
Some College 528 46.0 399 46.3 129 44.9   
College/Grad 379 33.0 274 31.8 105 36.6   
Marital Status             0.33 
Single/Never Married 648 56.4 494 57.3 154 53.8   
Married/Living with partner 395 34.4 295 34.2 100 35.0   
Separated/Divorced/Widowed 105 9.1 73 8.5 32 11.2   
BMI             0.61 
Underweight 25 2.2 17 2.0 8 2.8   
Normal 480 41.8 353 41.0 127 44.3   
Overweight 269 23.4 206 23.9 63 22.0   
Obese 374 32.6 285 33.1 89 31.0   
Low SES             0.23 
No 540 47.0 414 48.0 126 43.9   
Yes 609 53.0 448 52.0 161 56.1   
Insurance             0.48 
None 383 33.5 279 32.6 104 36.2   
Private 608 53.1 460 53.7 148 51.6   
Public 153 13.4 118 13.8 35 12.2   
Parity             0.22 
0 563 49.0 412 47.8 151 52.6   
1 253 22.0 200 23.2 53 18.5   
2 213 18.5 164 19.0 49 17.1   
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3+ 120 10.4 86 10.0 34 11.8   
Unintended Pregnancies             0.70 
0 509 44.3 377 43.8 132 46.0   
1 280 24.4 214 24.9 66 23.0   
2 185 16.1 143 16.6 42 14.6   
3+ 174 15.2 127 14.8 47 16.4   
History of abortion             0.09 
No 814 70.8 622 72.2 192 66.9   
Yes 335 29.2 240 27.8 95 33.1   
History of STI             0.09 
No 672 58.5 492 57.1 180 62.7   
Yes 477 41.5 370 42.9 107 37.3   
STI at time of baseline 
interview             0.27 
No 1028 92.8 765 92.3 263 94.3   
Yes 80 7.2 64 7.7 16 5.7   
History of depression and/or 
anxiety             0.12 
No 845 73.5 644 74.7 201 70.0   
Yes 304 26.5 218 25.3 86 30.0   
History of violence and/or 
abuse in lifetime             0.10 
No 272 45.0 211 46.9 61 39.4   
Yes 333 55.0 239 53.1 94 60.6   
History of dysmenorrhea             0.12 
Never or Sometimes 681 65.2 501 63.9 180 69.2   
Often or Always 363 34.8 283 36.1 80 30.8   
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Table 2: Experienced Pain by Participant Characteristics: Unadjusted Relative Risks for 
Dichotomous Outcome (Pain Score > 7) 
 
  
Mean 
Experienced 
Pain Score 
Pain Score  
(> 7) 
Unadjusted 
Relative 
Risk 95% CI 
Age group           
<20 years old 5.6 37.07 1.36 1.05 1.76 
>=20 years old 4.9 27.3       
Race           
Black 4.5 22.8 0.70 0.58 0.86 
White 5.3 32.35       
Others 5.5 33.78 1.04 0.74 1.47 
Ethnicity           
Hispanic 5.7 40       
Non-Hispanic 4.9 27.81 0.70 0.48 1.01 
Education           
<=HS 4.9 28.93       
Some College 4.9 26.89 0.93 0.73 1.18 
College/Grad 5.1 29.82 1.03 0.80 1.32 
Marital Status           
Single/Never 
Married 5.2 31.02       
Married/Living with 
partner 4.6 24.56 0.79 0.64 0.97 
Separated/Divorced
/Widowed 4.8 25.71 0.83 0.59 1.17 
BMI           
Underweight 5.5 40 1.16 0.71 1.91 
Normal 5.4 34.38       
Overweight 4.8 24.54 0.71 0.56 0.91 
Obese 4.4 22.46 0.65 0.52 0.82 
Low SES           
No 5.2 30.56       
Yes 4.7 26.27 0.86 0.72 1.03 
Insurance           
None 5 27.42 0.89 0.73 1.09 
Private 5.1 30.76       
Public 4.2 19.61 0.64 0.45 0.90 
Parity           
0 5.8 39.08       
1 4.8 20.95 0.54 0.41 0.70 
2 4.2 15.96 0.41 0.30 0.57 
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3+ 3.6 15 0.38 0.25 0.60 
Unintended 
Pregnancies           
0 5.6 36.15       
1 4.6 22.5 0.62 0.49 0.80 
2 4.7 25.41 0.70 0.54 0.92 
3+ 4 17.82 0.49 0.35 0.69 
History of abortion           
No 5.1 30.1       
Yes 4.7 23.88 0.79 0.64 0.99 
 History of STI           
No 5 28.42       
Yes 4.9 28.09 0.99 0.82 1.19 
STI at time of 
baseline interview           
No 5 28.5       
Yes 4.7 27.5 0.96 0.67 1.40 
History of 
depression and/or 
anxiety           
No 4.9 27.34       
Yes 5.2 30.92 1.13 0.93 1.38 
History of violence 
and/or abuse in 
lifetime           
No 4.4 19.49       
Yes 4.5 24.62 1.26 0.93 1.72 
History of 
dysmenorrhea           
No 4.7 22.61       
Yes 5.5 39.67 1.75 1.45 2.12 
Expected pain*           
< median  4 15.15       
> median 5.5 35.19 2.32 1.80 2.99 
Type of IUD           
LNG-IUS 5.1 29.58       
Copper 4.7 24.39 0.82 0.66 1.04 
* Expected pain was analyzed as a continuous variable in the multivariable model.  
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Table 3:  Adjusted Analysis for the Association of Patient Characteristics, IUD Type, 
Anticipated Pain and Experienced Pain 
 
 
 
Characteristic   Adjusted Relative Risk 95% Confidence Interval 
 
 
Parity   0    1.0 (referent) 
   1    0.61   0.47, 0.80 
   2    0.48   0.35, 0.66 
   3+    0.45   0.29, 0.71 
 
History of Dysmenorrhea      1.53   1.28, 1.83 
Copper IUD 
   (compared to LNG-IUS)    0.76   0.61, 0.95    
 
Anticipated Pain       1.19   1.14, 1.25 
 
 
 
 
IUD = intrauterine device 
LNG-IUS = levonorgestrel intrauterine system 
 
 
 
